Orlando, FL (PRWEB) September 07, 2012
The Pradaxa Resource Center, a patient advocacy group, is alerting those prescribed the blood thinner Pradaxa that experts have linked the drug to severe internal bleeding. Also, a federal judge recently scheduled a hearing to discuss the handling of mounting lawsuits filed against the manufacturer.
Anyone affected by internal bleeding or the loss of a loved one after Pradaxa use is urged to speak with a lawyer about their legal rights as soon as possible.
Pradaxa is a popular blood thinner prescribed to prevent strokes and blood clots in patients with atrial fibrillation. According to the Berlin Ad Hoc News on August 27, 2012, manufacturer Boehringer Ingelheim has announced that Pradaxa has now reached one million patient-years of combined prescription time, with use in more than 70 countries worldwide.
On December 7, 2011, however, the FDA warned that it would launch an investigation into Pradaxa after receiving more injury or death reports than expected. According to a USA Today article on August 19, 2012, the agency received 3,781 reports of side effects and 542 deaths among Pradaxa users last year, leading all other medications in 2011.
Due to the number of Pradaxa lawsuits expected, a central court was recently established in Illinois to handle the claims. The case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
On July 17, 2012, Judge David Herndon, who will oversee the litigation, issued an order titled “Case Management Order Number 1 – Initial Conference Order and Procedural Matters”, which set an initial hearing for October 3, 2012 at 1:30 p.m, and indicated trials should start in 18 to 24 months.
Since litigation is moving forward, anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of these federal MDL cases, the Pradaxa Resource center only recommends lawyers who are already handling Pradaxa lawsuits.